Form 4: IMMUCELL CFO Fiori Granted 120,000 Stock Options

IMMUCELL Corporation's CFO, Timothy C. Fiori, was granted 120,000 stock options with an exercise price of $6.265, vesting over three years.

Summary

• Timothy C. Fiori, Chief Financial Officer and Director of IMMUCELL CORP /DE/ (ICCC), was granted 120,000 stock options.
• The options have an exercise price of $6.265 per share.
• The grant date for these options was January 27, 2026, and they expire on January 27, 2036.
• The options vest in three equal annual installments of 40,000 options on the first, second, and third anniversary of the grant date.
• The options are intended to be treated as incentive stock options to the maximum extent permitted by the International Revenue Code of 1986, with any balance treated as nonqualified stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it aligns executive incentives with shareholder interests, which is generally beneficial for long-term company performance, without indicating any immediate operational or financial changes.

Positives

• The stock option grant aligns the Chief Financial Officer's long-term financial interests with those of the shareholders, incentivizing performance and stock price appreciation.
• The vesting schedule encourages executive retention and sustained commitment to the company's success over a three-year period.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholder equity, though this is a common aspect of equity-based compensation.

Risks

• The value of the stock options is dependent on the future market price of IMMUCELL's common stock exceeding the exercise price of $6.265, exposing the options to market risk.
• If the company's stock price does not perform well, the options may not provide significant value to the holder.

Future Outlook

The option grant, with its ten-year expiration and three-year vesting schedule, indicates a long-term commitment from the Chief Financial Officer to the company's future performance and growth.

Industry Context

Stock option grants are a standard component of executive compensation packages across various industries, particularly in publicly traded companies. StockSavvy.ai notes that this practice is designed to align executive incentives with shareholder value creation by tying a portion of compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a common executive compensation practice, comparable to similar grants observed at companies like Zoetis Inc. (ZTS) or Elanco Animal Health Incorporated (ELAN) within the animal health sector, where equity incentives are used to attract and retain key talent.
• The vesting schedule of three years is typical for executive equity awards, aiming to foster long-term commitment and performance, similar to structures seen in many biotech and pharmaceutical companies.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned management incentives for stock price appreciation.
• Employees: The CFO's compensation structure is a component of the overall employee compensation strategy, potentially influencing morale and retention at the executive level.

Next Steps

• The options will vest in three annual installments of 40,000 options on the first, second, and third anniversaries of the January 27, 2026 grant date.

Key Dates

Keywords

IMMUCELL, ICCC, Stock Options, Executive Compensation, Form 4, Insider Transaction, Timothy C. Fiori, CFO, Equity Grant